<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274897</url>
  </required_header>
  <id_info>
    <org_study_id>V59_39</org_study_id>
    <nct_id>NCT01274897</nct_id>
  </id_info>
  <brief_title>A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea</brief_title>
  <official_title>A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the immunogenicity and the safety of a quadrivalent
      vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</measure>
    <time_frame>day 29</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with hSBA response and associated 95% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y by serum bactericidal assay using human complement, human serum bactericidal assay (hSBA), at day 29 (28 days after MenACWY-CRM vaccination).
Seroresponse is defined as:
for subjects with a pre-vaccination hSBA titer &lt; 1:4, a postvaccination hSBA titer ≥ 1:8.
for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</measure>
    <time_frame>day 1 and day 29</time_frame>
    <description>Immunogenicity was assessed as hSBA GMTs and associated 95% CI, measured against N. meningitidis serogroups A, C, W and Y, before the vaccination (baseline, day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</measure>
    <time_frame>day 1 and day 29</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI, at baseline before vaccination (day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Local and Systemic Reactogenicity During 7 Days After MenACWY-CRM Vaccination</measure>
    <time_frame>during 7 days of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received the saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis MenACWY-CRM</intervention_name>
    <description>All subjects had blood drawn at Day 1 and Day 29.</description>
    <arm_group_label>MenACWY-CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>All subjects had blood drawn at Day 1 and Day 29.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals eligible for enrollment in this study were those:

          1. who were 11-55 years of age inclusive and who, after the nature of the study had been
             explained:

               1. had given written assent and/or for whom the parent/legal representative had
                  provided written informed consent (11-19 years of age).

               2. had provided written informed consent (20-55 years of age).

          2. who the investigator believed that they or their parents/legal representatives would
             comply with the requirements of the protocol (e.g., completion of the Diary Card,
             return for follow-up visit).

          3. who were in good health as determined by

               1. medical history

               2. physical assessment

               3. clinical judgment of the investigator

          4. who had negative urine pregnancy test for women of childbearing age.

        Exclusion Criteria:

        Individuals not eligible to be enrolled in the study were those:

          1. who were unwilling or unable to give written informed assent or consent to participate
             in the study.

          2. who were perceived to be unreliable or unavailable for the duration of the study
             period.

          3. who were planning to leave the area of the study site before the end of the study
             period.

          4. who had a previous or suspected disease caused by N. meningitidis.

          5. who had household contact with and/or intimate exposure to an individual with
             culture-proven N. meningitidis infection within 60 days prior to enrollment.

          6. who had previously been immunized with a meningococcal vaccine.

          7. who had received any investigational or non-registered product (drug or vaccine)within
             28 days prior to enrollment or who expected to receive an investigational drug or
             vaccine prior to the completion of the study.

          8. who had received any licensed vaccines within 14 days (for inactivated vaccines) or 28
             days (for live vaccines) prior to enrollment in this study or who were planning to
             receive any vaccine within 30 days from the study vaccines. (Exception: Influenza
             vaccine was administered up to 15 days prior to study vaccination and at least 15 days
             after study vaccination)

          9. who had experienced within the 7 days prior to enrollment significant acute or chronic
             infection (for example requiring systemic antibiotic treatment or antiviral therapy)
             or had experienced fever (defined as body temperature ≥38°C) within 3 days prior to
             enrollment.

         10. who had any serious acute, chronic or progressive disease (e.g., any history of
             neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or
             AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe
             malnutrition).

         11. who had epilepsy or any progressive neurological disease.

         12. who had a history of any anaphylaxis, serious vaccine reactions, or allergy to any
             vaccine components, including latex allergies.

         13. who had a known or suspected impairment/alteration of immune function, either
             congenital or acquired or resulting from (for example):

               1. received immunosuppressive therapy within 28 days prior to enrollment(any
                  systemic corticosteroid administered for more than 5 days, or in a daily dose &gt; 1
                  mg/kg/day prednisone or equivalent during any of 28 days prior to enrollment, or
                  cancer chemotherapy)

               2. received immunostimulants

               3. received parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within 90 days prior to enrollment and for the full length of the
                  study

         14. who were known to have a bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time.

         15. who had any condition that, in the opinion of the investigator, might interfere with
             the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaprtment of Pediatrics, Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases, Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent medicine, Myongji Hospital Kwandong University</name>
      <address>
        <city>Kyunggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infection Diseases, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases, Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>March 13, 2012</results_first_submitted>
  <results_first_submitted_qc>September 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2012</results_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>ACWY-CRM</keyword>
  <keyword>Conjugate Vaccine</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Persistence</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 8 centres in the Korea.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-CRM</title>
          <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects received the saline placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-CRM</title>
          <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received the saline placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="297"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="450"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age, Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="9.2"/>
                    <measurement group_id="B2" value="19.3" spread="8.9"/>
                    <measurement group_id="B3" value="19.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
        <description>Immunogenicity was measured as the percentage of subjects with hSBA response and associated 95% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y by serum bactericidal assay using human complement, human serum bactericidal assay (hSBA), at day 29 (28 days after MenACWY-CRM vaccination).
Seroresponse is defined as:
for subjects with a pre-vaccination hSBA titer &lt; 1:4, a postvaccination hSBA titer ≥ 1:8.
for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
        <time_frame>day 29</time_frame>
        <population>Analysis was done on per protocol (PP) population i.e. the subjects who received the vaccine correctly and provided evaluable serum samples at the relevant time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received the saline placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
          <description>Immunogenicity was measured as the percentage of subjects with hSBA response and associated 95% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y by serum bactericidal assay using human complement, human serum bactericidal assay (hSBA), at day 29 (28 days after MenACWY-CRM vaccination).
Seroresponse is defined as:
for subjects with a pre-vaccination hSBA titer &lt; 1:4, a postvaccination hSBA titer ≥ 1:8.
for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.</description>
          <population>Analysis was done on per protocol (PP) population i.e. the subjects who received the vaccine correctly and provided evaluable serum samples at the relevant time points.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (N=295,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="71" upper_limit="81"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=293,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="82" upper_limit="90"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (N=293,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=294,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="63" upper_limit="74"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis associated with the primary immunogenicity objective is that for at least one of the four serogroups, the percentage of subjects with hSBA seroresponse at 29 days postvaccination is &lt; 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Lower limit of the two-sided 95% CI</param_type>
            <param_value>71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71</ci_lower_limit>
            <ci_upper_limit>81</ci_upper_limit>
            <estimate_desc>For serogroup A.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis associated with the primary immunogenicity objective is that for at least one of the four serogroups, the percentage of subjects with hSBA seroresponse at 29 days postvaccination is &lt; 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Lower limit of the two-sided 95% CI</param_type>
            <param_value>82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82</ci_lower_limit>
            <ci_upper_limit>90</ci_upper_limit>
            <estimate_desc>For the serogroup C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis associated with the primary immunogenicity objective is that for at least one of the four serogroups, the percentage of subjects with hSBA seroresponse at 29 days postvaccination is &lt; 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Lower limit of the two-sided 95% CI</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23</ci_lower_limit>
            <ci_upper_limit>33</ci_upper_limit>
            <estimate_desc>For the serogroup W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis associated with the primary immunogenicity objective is that for at least one of the four serogroups, the percentage of subjects with hSBA seroresponse at 29 days postvaccination is &lt; 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Lower limit of the two-sided 95% CI</param_type>
            <param_value>63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63</ci_lower_limit>
            <ci_upper_limit>74</ci_upper_limit>
            <estimate_desc>For serogroup Y</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
        <description>Immunogenicity was assessed as hSBA GMTs and associated 95% CI, measured against N. meningitidis serogroups A, C, W and Y, before the vaccination (baseline, day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
        <time_frame>day 1 and day 29</time_frame>
        <population>Analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received the saline placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
          <description>Immunogenicity was assessed as hSBA GMTs and associated 95% CI, measured against N. meningitidis serogroups A, C, W and Y, before the vaccination (baseline, day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
          <population>Analysis was done on PP population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A at Day 1 (N=295,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.47" upper_limit="2.95"/>
                    <measurement group_id="O2" value="2.86" lower_limit="2.53" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A at Day 29 (N=295,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39" upper_limit="57"/>
                    <measurement group_id="O2" value="3" lower_limit="2.31" upper_limit="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C at Day 1 (N=293,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" lower_limit="6.76" upper_limit="9.05"/>
                    <measurement group_id="O2" value="5.94" lower_limit="4.85" upper_limit="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C at Day 29 (N=293,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" lower_limit="198" upper_limit="269"/>
                    <measurement group_id="O2" value="6.04" lower_limit="4.89" upper_limit="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W at Day 1 (N=293,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="44" upper_limit="61"/>
                    <measurement group_id="O2" value="48" lower_limit="38" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W at Day 29 (N=293,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" lower_limit="125" upper_limit="171"/>
                    <measurement group_id="O2" value="47" lower_limit="38" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y at Day 1 (N=294,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" lower_limit="7.64" upper_limit="11"/>
                    <measurement group_id="O2" value="8.82" lower_limit="7.02" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y at Day 29 (N=294,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="89" upper_limit="128"/>
                    <measurement group_id="O2" value="8.4" lower_limit="6.54" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
        <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI, at baseline before vaccination (day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
        <time_frame>day 1 and day 29</time_frame>
        <population>Analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received the saline placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.</title>
          <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI, at baseline before vaccination (day 1) and at day 29 (28 days after MenACWY-CRM vaccination).</description>
          <population>Analysis was done on PP population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A at Day 1 (N=295,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="17"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A at Day 29 (N=295,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="74" upper_limit="84"/>
                    <measurement group_id="O2" value="16" lower_limit="10" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C at Day 1 (N=293,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="44" upper_limit="55"/>
                    <measurement group_id="O2" value="39" lower_limit="31" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C at Day 29 (N=293,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="37" lower_limit="30" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W at Day 1 (N=293,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="85" upper_limit="92"/>
                    <measurement group_id="O2" value="87" lower_limit="80" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W at Day 29 (N=293,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="88" lower_limit="82" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y at Day 1 (N=294,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="48" upper_limit="60"/>
                    <measurement group_id="O2" value="53" lower_limit="44" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y at Day 29 (N=294,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O2" value="51" lower_limit="42" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Local and Systemic Reactogenicity During 7 Days After MenACWY-CRM Vaccination</title>
        <time_frame>during 7 days of vaccination</time_frame>
        <population>Analysis was done on safety population i.e. the subjects in the exposed population who provided post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received the saline placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Local and Systemic Reactogenicity During 7 Days After MenACWY-CRM Vaccination</title>
          <population>Analysis was done on safety population i.e. the subjects in the exposed population who provided post-baseline safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axillary temperature (&lt;38.0°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Used analgesic or antipyretic medicines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period (29 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MenACWY-CRM</title>
          <description>Subjects received one dose of MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects received the saline placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="297"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="297"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="297"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="297"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="297"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

